Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.46 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21644144 | 0.86 | DYRK1A (0.59) | CHEK1GSK3BDYRK1ATGFBR1FYN | |
| SCHEMBL13336494 | 0.83 | NPC1 (0.51) | ALDH1A1KDM4EHSD17B10DYRK1AKDR | |
| SCHEMBL24155477 | 0.81 | MEN1 (0.44) | CHEK1GSK3BDYRK1AKDRMAP4K4 | |
| SCHEMBL16304078 | 0.79 | KEAP1 (0.44) | ALDH1A1KDM4EDYRK1ATGFBR1RET | |
| SCHEMBL20190385 | 0.79 | MCHR1 (0.51) | ALDH1A1KDM4EHPGDDYRK1AMKNK1 | |
| SCHEMBL30549526 | 0.78 | TGFBR1 (0.44) | KDM4EDYRK1ACDK8MAP2K1ROCK1 | |
| SCHEMBL19781540 | 0.76 | CYP1A2 (0.54) | ALDH1A1KDM4EGLADYRK1AMAP4K4 | |
| SCHEMBL20208560 | 0.76 | KDM4E (0.55) | ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL26146291 | 0.75 | MET (0.53) | CHEK1FYNPIM1PIM3 | |
| SCHEMBL1576521 | 0.74 | DYRK1A (0.73) | CHEK1ALDH1A1DYRK1AKDRMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143306-A1 | LUCIFERASE LINKED IMMUNOSORBENT ASSAY | Institut Pasteur (FR) | 2023-03-08 | — | — | EP | disclosed |
| CN-102066377-B | Novel phenylimidazopyrazines | HOFFMANN LA ROCHE | 2014-11-19 | — | — | CN | disclosed |
| EP-2307418-B1 | NOVEL PHENYLIMIDAZOPYRAZINES | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| JP-5341187-B2 | — | — | 2013-11-13 | — | — | JP | disclosed |
| US-8426409-B2 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426409-B2 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC (US) | 2013-04-23 | — | — | US | disclosed |
| CN-102066377-A | Novel phenylimidazopyrazines | HOFFMANN LA ROCHE | 2011-05-18 | — | — | CN | disclosed |
| EP-2307418-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| EP-2307418-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010006970-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010006970-A1 | NOVEL PHENYLIMIDAZOPYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | ROCHE PALO ALTO LLC | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016302-A1 | 7-tert-Butyl-3-(3-{8-[4-(morpholine-4-carbonyl)-phenylamino]-imidazo[1,2-a]pyrazin-6-yl}-phenyl)-3H-quinazolin-4-one; arthritis; inhibit Btk | BTK, LCK, LYN | CHEK1 699/4885GSK3B 1162/4885ALDH1A1 3855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.